CN101283965B - 一种含左旋多巴甲酯的制剂及制备方法 - Google Patents
一种含左旋多巴甲酯的制剂及制备方法 Download PDFInfo
- Publication number
- CN101283965B CN101283965B CN200710134034XA CN200710134034A CN101283965B CN 101283965 B CN101283965 B CN 101283965B CN 200710134034X A CN200710134034X A CN 200710134034XA CN 200710134034 A CN200710134034 A CN 200710134034A CN 101283965 B CN101283965 B CN 101283965B
- Authority
- CN
- China
- Prior art keywords
- ldme
- preparation
- solid dispersion
- methyl ester
- lactose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 37
- -1 bendopa methyl ester Chemical class 0.000 title 1
- XBBDACCLCFWBSI-ZETCQYMHSA-N melevodopa Chemical compound COC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 XBBDACCLCFWBSI-ZETCQYMHSA-N 0.000 claims abstract description 63
- 239000007962 solid dispersion Substances 0.000 claims abstract description 52
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 19
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims abstract description 19
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 19
- 239000002775 capsule Substances 0.000 claims abstract description 15
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 12
- 239000012876 carrier material Substances 0.000 claims abstract description 8
- 229920001993 poloxamer 188 Polymers 0.000 claims abstract description 8
- 239000008187 granular material Substances 0.000 claims abstract description 7
- 239000003826 tablet Substances 0.000 claims abstract description 5
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims abstract 2
- 229940044519 poloxamer 188 Drugs 0.000 claims abstract 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 20
- 239000008101 lactose Substances 0.000 claims description 20
- 238000001291 vacuum drying Methods 0.000 claims description 8
- 238000007500 overflow downdraw method Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 abstract description 55
- 229940079593 drug Drugs 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 12
- 238000003756 stirring Methods 0.000 abstract description 9
- 239000006185 dispersion Substances 0.000 abstract description 7
- 230000002496 gastric effect Effects 0.000 abstract description 7
- 208000018737 Parkinson disease Diseases 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract description 2
- 229960001794 melevodopa Drugs 0.000 abstract 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- 230000004927 fusion Effects 0.000 description 13
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 10
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 9
- 229920001983 poloxamer Polymers 0.000 description 9
- 229960000502 poloxamer Drugs 0.000 description 9
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 8
- 229960004502 levodopa Drugs 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000010298 pulverizing process Methods 0.000 description 5
- 239000008118 PEG 6000 Substances 0.000 description 4
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 4
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 229920003081 Povidone K 30 Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 101710151768 Aromatic-L-amino-acid decarboxylase Proteins 0.000 description 1
- 229940081615 DOPA decarboxylase inhibitor Drugs 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 108010035075 Tyrosine decarboxylase Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229920005601 base polymer Polymers 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000534 dopa decarboxylase inhibitor Substances 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710134034XA CN101283965B (zh) | 2007-10-26 | 2007-10-26 | 一种含左旋多巴甲酯的制剂及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710134034XA CN101283965B (zh) | 2007-10-26 | 2007-10-26 | 一种含左旋多巴甲酯的制剂及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101283965A CN101283965A (zh) | 2008-10-15 |
CN101283965B true CN101283965B (zh) | 2010-06-16 |
Family
ID=40056522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200710134034XA Active CN101283965B (zh) | 2007-10-26 | 2007-10-26 | 一种含左旋多巴甲酯的制剂及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101283965B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101810586B (zh) * | 2010-04-29 | 2013-05-01 | 上海交通大学 | 左旋多巴甲酯缓释微球组合物及其制备方法 |
CN101884623B (zh) * | 2010-07-20 | 2012-01-18 | 上海交通大学医学院附属新华医院 | 一种左旋多巴甲酯缓释微球组合物及其制备方法 |
CN101879143B (zh) * | 2010-07-20 | 2011-10-05 | 上海交通大学医学院附属新华医院 | 一种含有抗帕金森病药物的微球组合药物及其应用 |
CN101879153B (zh) * | 2010-07-20 | 2011-12-07 | 上海交通大学医学院附属新华医院 | 一种左旋多巴甲酯和苄丝肼混和药物缓释微球组合物及其制备方法 |
CN102258491B (zh) * | 2011-07-19 | 2012-10-24 | 山东省中医药研究院 | 一种熊果酸滴丸及其制备方法 |
CN111214450B (zh) * | 2020-04-23 | 2020-07-17 | 上海翰森生物医药科技有限公司 | 恩格列净片及其制备工艺 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5017607A (en) * | 1986-06-10 | 1991-05-21 | Chiesi Farmaceutici S.P.A. | Method to treat Parkinsons disease |
-
2007
- 2007-10-26 CN CN200710134034XA patent/CN101283965B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5017607A (en) * | 1986-06-10 | 1991-05-21 | Chiesi Farmaceutici S.P.A. | Method to treat Parkinsons disease |
Also Published As
Publication number | Publication date |
---|---|
CN101283965A (zh) | 2008-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190343840A1 (en) | Risperidone sustained release microsphere composition | |
CN101141961B (zh) | 索非那新或其盐的稳定的颗粒状药物组合物 | |
CN101283965B (zh) | 一种含左旋多巴甲酯的制剂及制备方法 | |
KR101524164B1 (ko) | 방출 제어 의약 조성물 | |
JP5147703B2 (ja) | 経口投与でき、かつ活性成分の迅速な放出を有する固形医薬投与形態 | |
JP3563036B2 (ja) | セレコキシブ組成物 | |
KR101527254B1 (ko) | 저치환도 히드록시프로필셀룰로오스 및 이것을 포함하는 고형 제제 | |
CN102946869A (zh) | γ-羟基丁酸的速释制剂及剂型 | |
CN104650091B (zh) | 替格瑞洛的微粉化及其晶型,以及制备方法和药物应用 | |
CN101516338A (zh) | 一种含有非诺贝特的口服药物组合物及其制备方法 | |
CN102307579B (zh) | 经口给药用医药组合物 | |
BG66007B1 (bg) | Компресиран таблетен състав съдържащ нестероидно противовъзпалително средство | |
CN102793680A (zh) | 阿齐沙坦固体分散体及其制备方法和药物组合物 | |
CN103260605B (zh) | 阿齐沙坦固体分散体及其制备方法和药物组合物 | |
KR100908418B1 (ko) | 퀴놀리논 유도체 의약 조성물 및 그의 제조 방법 | |
CN105496966A (zh) | 一种恩格列净固体分散体的药物组合物及其制备方法 | |
CN1899277B (zh) | 大黄酸或大黄酸类化合物的复合物、其制备方法及其在制备治疗糖尿病肾病药物中的应用 | |
JP7536098B2 (ja) | ウチデロンの経口固形製剤 | |
WO2007108463A1 (ja) | 溶解性が改善された固形製剤 | |
CN101721351A (zh) | 奈比洛尔或其药用盐固体分散体、其制备方法及其应用 | |
JP6072705B2 (ja) | 固体分散体製剤 | |
CN104248769B (zh) | 一种鲁拉西酮药物组合物及其制备方法 | |
CN101103981A (zh) | 含他克莫司的药物组合物 | |
CN103284952A (zh) | 一种含有非诺贝特的药物组合物 | |
CN110917200A (zh) | 一种包含微粉化形式的口服固体药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: C + O PHARMACEUTICAL TECHNOLOGY (HOLDINGS) LTD. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20110310 Address after: 210038 No. 1 Heng Fei Road, Nanjing economic and Technological Development Zone, Jiangsu, China Co-patentee after: C & O Pharmaceutical Technology (Holdings) Ltd. Patentee after: Chang'ao Science and Technology of Medical Industry Co., Ltd., Nanjing Address before: 210038 No. 1 Heng Fei Road, Nanjing economic and Technological Development Zone, Jiangsu, China Patentee before: Chang'ao Science and Technology of Medical Industry Co., Ltd., Nanjing |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: No. 63 Kexin Road, Jiangbei New District, Nanjing City, Jiangsu Province, 210000 Co-patentee after: C & O Pharmaceutical Technology (Holdings) Ltd. Patentee after: Chang'ao Science and Technology of Medical Industry Co., Ltd., Nanjing Address before: 210038 No. 1 Heng Fei Road, Nanjing economic and Technological Development Zone, Jiangsu, China Co-patentee before: C & O Pharmaceutical Technology (Holdings) Ltd. Patentee before: Chang'ao Science and Technology of Medical Industry Co., Ltd., Nanjing |
|
CP02 | Change in the address of a patent holder |
Address after: 210038 Nanjing economic and Technological Development Zone, Jiangsu Province, No. Wing Road, No. 1 Patentee after: Nanjing Changao Pharmaceutical Science & Technology Co.,Ltd. Patentee after: CHANG'AO PHARMACEUTICAL TECHNOLOGY (HOLDINGS) Ltd. Address before: No. 63 Kexin Road, Jiangbei New District, Nanjing City, Jiangsu Province, 210000 Patentee before: Nanjing Changao Pharmaceutical Science & Technology Co.,Ltd. Patentee before: CHANG'AO PHARMACEUTICAL TECHNOLOGY (HOLDINGS) Ltd. |
|
CP02 | Change in the address of a patent holder |